Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Change in Receivables: 2020-2023

Historic Change in Receivables for SAB Biotherapeutics (SABS) over the last 4 years, with Dec 2023 value amounting to -$5.6 million.

  • SAB Biotherapeutics' Change in Receivables fell 110.86% to -$361,735 in Q3 2023 from the same period last year, while for Sep 2023 it was -$12.9 million, marking a year-over-year decrease of 574.27%. This contributed to the annual value of -$5.6 million for FY2023, which is 126.42% down from last year.
  • According to the latest figures from FY2023, SAB Biotherapeutics' Change in Receivables is -$5.6 million, which was down 126.42% from -$2.5 million recorded in FY2022.
  • In the past 5 years, SAB Biotherapeutics' Change in Receivables ranged from a high of $17.8 million in FY2020 and a low of -$12.6 million during FY2021.
  • Over the past 3 years, SAB Biotherapeutics' median Change in Receivables value was -$5.6 million (recorded in 2023), while the average stood at -$6.9 million.
  • Per our database at Business Quant, SAB Biotherapeutics' Change in Receivables plummeted by 170.75% in 2021 and then spiked by 80.46% in 2022.
  • Yearly analysis of 4 years shows SAB Biotherapeutics' Change in Receivables stood at $17.8 million in 2020, then plummeted by 170.75% to -$12.6 million in 2021, then surged by 80.46% to -$2.5 million in 2022, then plummeted by 126.42% to -$5.6 million in 2023.